Therefore, everolimus mediated inhibition of mTOR activity may exert differential outcomes in COVID-19 patients by mitigating the cytokine storm and hyper-reactivity in the critical phase of the disease (Terrazzano et al., 2020; Ye et al., 2020). The gene discussed is MTOR; the disease is COVID-19.